ArticleLangmuir : the ACS journal of surfaces and colloids2025
Concentrated Polymer Brush-Modified Magnetic Particles for a Diagnostic Immunoassay.
Article in Langmuir : the ACS journal of surfaces and colloids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonspecific protein absorption is an ongoing problem in the development of highly sensitive magnetic particle (MP)-based diagnostic assays, whereby the MP surface undergoes biofouling, significantly reducing the limit of detection and sensitivity of the device. In this study, a bioinert, concentrated polymer brush (CPB) composed of poly[poly(ethylene oxide) methyl ether methacrylate] (PPEGMA) was employed to reduce the absorption of protein onto the MP surfaces; and an anti-human serum albumin antibody (Ab) was then immobilized onto the brush layer by click chemistry to demonstrate its application as an immunoassay platform. The amount of antibody grafted onto the ends of the brush coating was quantified by a BCA assay with a high grafting efficiency (∼0.80 antibody per chain). Furthermore, when using the antibody-conjugated CPB-coated MPs (MP-PPEGMA-Ab) as an immunoassay platform, we were able to determine the capture efficacy of human serum albumin (HSA) in both a buffered solution and diluted human serum by colorimetric analysis, and further confirmation was achieved via liquid chromatography/mass spectrometry, in which our MPs showed a high selectivity toward the targeted analyte. Lastly, we demonstrated that MP-PPEGMA-Ab was capable of detecting human serum albumin at a concentration as low as 6.4 ng mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.